Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

Roche for the novel anti-cancer antibody TB-403 is also going well, as evidenced by the success fee that we received from them earlier in the year."

"ThromboGenics' business has never been so well placed. We have a clear strategy, an exciting lead product in microplasmin and two further assets in TB-402 and TB-403 which will provide us with further opportunities to deliver value for our shareholders."

    Financial Update

    - ThromboGenics achieved revenues of EUR3.6 million in the
      first half of 2009, nearly all of which came from a success fee from
      Roche, our partner for TB-403. R&D expenses were EUR8.8 million during
      this six month period. In addition EUR5.7 million of expenses related
      to the microplasmin Phase III clinical program (called MIVI TRUST) have
      been capitalized. General and administrative costs in the first half
      increased from EUR1.2 million to EUR1.7 million due to higher one-time
      legal costs, in part due to the merger of ThromboGenics NV and
      ThromboGenics Ltd. In the first half, ThromboGenics made a net loss of
      EUR4.7 million.

    - As of June 30, 2009, ThromboGenics had EUR52.6 million in
      cash and cash equivalents. This compares to EUR40.4 million on June 30,
      2008 and EUR58.9 million on December 31, 2008. The cash figure at the
      end of June includes the EUR3.1 million that ThromboGenics received in
      May as a result of the exercise of warrants. The Company's cash
      resources are expected to allow ThromboGenics to execute its current
      operational plans for approximately the next two years.


    Business Highlights
    Clinical Highlights

Microplasmin - Back of the Eye Disease: Phase III clinical program to evaluate non-surgical treatment of patients with vitreomacular adhesion.

    - Phase III program continues to progress well, with
      recruitment on track


'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... LYNBROOK, N.Y., June 29 BioSpecifics Technologies Corp. (Nasdaq: ... collagenase-based products, announced today that it was added to the ... of the U.S. markets on June 29, 2009. The Russell ... to be a comprehensive representation of the investable U.S. equity ...
... Kendle (Nasdaq: KNDL ), a leading, ... of Jarrod Pontius to the position of Chief Legal ... leadership for all legal services, corporate governance and general ... based in Kendle,s global headquarters in Cincinnati and will ...
... , , , BATESVILLE, Ind., June ... the sale of Hill-Rom,s patents and intellectual property relating to ... KCI ). Hill-Rom,s NPWT portfolio included U.S. ... components, protocols, and related therapies. The transaction is effective immediately. ...
Cached Biology Technology:BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes 2Kendle Names Jarrod Pontius Chief Legal Officer 2Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property 2Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property 3
(Date:4/17/2014)... Texas Medical Branch at Galveston are the first ... for cervical cancer should begin colorectal cancer screening ... researchers, finding a high incidence of secondary colorectal ... offer new recommendations that the younger women in ... years after their initial cervical cancer diagnosis instead ...
(Date:4/17/2014)... from Charles Darwin, whose ideas in turn were ... 19th century, a period when landowners vigorously pursued ... Darwin that we inherit the ideas that domestication ... and total human control over breeding and animal ... setting has been applied too broadly in time ...
(Date:4/16/2014)... cannot lift your upper eyelid. You walk through life with your ... are rolled down in the eye socket. Obviously, such a condition ... head. In order to correct this condition, one would need to ... April 16 print issue of the journal Neuron , University ...
Breaking Biology News(10 mins):Radiation therapy for cervical cancer increases risk for colorectal cancer 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Researchers track down cause of eye mobility disorder 2
... City once topped lists of places with the worst air ... improved the situation, tiny particles called aerosols still clog the ... other institutions have sorted through the pall that hangs over ... haze and chart daily patterns of changes to the mix. ...
... SEPTEMBER 2, 2008 Varying the rate of crop production ... as farmers have long observed differences in crop yield ... of spatial yield information from combines equipped with yield ... So, optimizing inputs to match yield potential ...
... visitor might blink twice at the sight of a ... the northern edge of Arizona State University (ASU), is ... canals and dams combining flood control, water delivery, recreational ... and economics in the area. What are ...
Cached Biology News:Smoke smudges Mexico City's air, chemists identify sources 2Smoke smudges Mexico City's air, chemists identify sources 3A little nitrogen can go a long way 2A little nitrogen can go a long way 3Evolving designer ecosystem sheds light on unintended consequences 2Evolving designer ecosystem sheds light on unintended consequences 3Evolving designer ecosystem sheds light on unintended consequences 4
... For use in hybridization incubators ... and GL 45 size PP plug-seal ... seal. Available in three lengths to ... plug-seal caps and O-rings available separately. ...
... Rapid, efficient extraction of DNA from agarose gels ... of DNA fragments of 150 bp to > 12,000 ... GelMelt solution to dissolve the gel slice, followed by ... a spin column format. After a wash step, the ...
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
Biology Products: